Applied Biosystems™

TaqPath™ COVID-19 High Throughput Combo Kit

Catalog number: A49869
Applied Biosystems™

TaqPath™ COVID-19 High Throughput Combo Kit

Catalog number: A49869
Catalog Number
A49869
Unit Size
20000 reactions
Price (USD)
Catalog NumberUnit SizePrice (USD)
A4986920000 reactions
Product Overview
Figures
Videos
Documents
FAQ
Citations & References
Additional Information
Recommendations
The TaqPath COVID-19 High Throughput Combo Kit consists of assays and controls for 20,000 real-time RT-PCR tests for the detection of SARS-COV-2 RNA in preserved saliva, nasal, and nasopharyngeal samples. Clinical laboratories can run up to 8,000 tests in 24 hours using the Amplitude Solution, and the assay kit enables efficient ordering to address high-throughput testing needs.

Features of the TaqPath COVID-19 high-throughput kit include:
• Available with 20,000 reactions per kit for preserved saliva and nasopharyngeal samples to help maximize specimen throughput
• Targeted specificity to 100% of currently available complete genomes for SARS-CoV-2
• Targets spike (S) protein and nucleocapsid (N) protein regions having higher specificity and exhibiting lower risk for mutation

This combo kit contains the TaqPath COVID-19 Module 1 MS2 Phage Control, TaqPath COVID-19 Module 2 Assay Kit, and TaqPath COVID-19 Module 2 Control Dilution Buffer. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in preserved saliva, nasopharyngeal, and nasal swab specimens during the acute phase of infection. (See product label for Intended Use Statement and product information). The TaqPath COVID-19 Combo Kit is ordered as a single, high-throughput (20,000 reactions) kit and is intended to use with the Amplitude Solution.

The content provided herein may relate to products or workflows that have not been officially CE Marked, authorized by the US FDA or global health agencies, and is subject to change without notice; Refer to current user manual for indications, warning and precautions. 

All validation data to support the Thermo Fisher Scientific Amplitude Solution has been completed and is currently under review by the Food and Drug Administration. Use of Thermo Fisher Scientific Amplitude Solution is permitted per FDA Policy for Coronavirus Disease-2019 Test during the Public Health Emergency (Revised) released on May 11, 2020.

The ordering of the Amplitude Solution reagents and consumables is managed by your Sales Representative in accordance with your laboratory Supply Agreement.

For Emergency Use Authorization (EUA) only. For prescription use only. For in vitro diagnostic use.

Specifications

For Use With (Application)
COVID-19 Diagnostic Testing
Quantity
20,000 Reactions
Species
Human
Target Organism Class
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Detection Method
Primer-Probe Detection
Shipping Condition
Wet ice
Product Line
TaqPath™

Contents & Storage

• TaqPath COVID-19 Module 2 Assay Kit, 6 x 2 mL per kit, 3 kits included, store at –10 to –30°C
• TaqPath COVID-19 Module 1 MS2 Phage Control, 6 x 15 mL per kit, 3 kits included, store at –10 to –30°C
• TaqPath COVID-19 Dilution Buffer, 3 x 2 mL per kit, 3 kits included, store at –10 to –30°C
• TaqPath COVID-19 Control, 3 x 2 µL per kit, 3 kits included, store at ≤ –70°C
• Product Insert

Figures

Frequently asked questions (FAQs)

Citations & References